Amphastar Pharmaceuticals (AMPH) Capital Expenditures (2013 - 2026)

Amphastar Pharmaceuticals' Capital Expenditures history runs 14 years deep, the most recent figure standing at $4.2 million for Q1 2026.

• On a quarterly basis, Capital Expenditures fell 42.17% year-over-year to $4.2 million in Q1 2026; TTM through Mar 2026 was $31.8 million, a 19.33% decrease from a year earlier, with the FY2025 full-year figure at $34.9 million, down 15.01% from the prior year.
• Capital Expenditures retreated to $4.2 million in Q1 2026 per AMPH's latest filing, from $8.3 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $35.9 million in Q4 2024 and bottomed at -$24.3 million in Q4 2023.
• The 5-year median for Capital Expenditures is $6.7 million (2022), against an average of $5.3 million.
• Across the five-year window, Capital Expenditures plunged 1429.86% in 2023 and surged 1376.77% in 2025, its largest moves.
• Year by year, Capital Expenditures stood at $1.8 million in 2022, then plunged by 1429.86% to -$24.3 million in 2023, then jumped by 248.01% to $35.9 million in 2024, then plunged by 76.97% to $8.3 million in 2025, then tumbled by 49.54% to $4.2 million in 2026.
• Per Business Quant, the three latest AMPH Capital Expenditures figures stand at $4.2 million (Q1 2026), $8.3 million (Q4 2025), and $20.6 million (Q3 2025).